Catalent today announced the appointment of Nakaya “Nick” Matsumaru as General Manager of its new clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan.

Passage Bio, Inc. and Catalent today announced that manufacturing operations have commenced to support adeno-associated virus (AAV) production for Passage Bio’s lead gene therapy product candidates for the treatment of rare monogenic CNS disorders.

Catalent’s clinical supply site in Bathgate has won Scottish Engineering’s ‘Vice President Award 2020,’ recognising its continuous improvement programme in core values including “patient first, customer dedication, people, innovation, integrity and excellence.”

Catalent today announced that it will lead multiple workshops and exhibit at the upcoming Global Clinical Supplies Group (GCSG) 2020 Global Virtual Conference, which takes place on Sept. 21-25, 2020.

Catalent today announced that Paul Ingram, Ph.D., Global Director, Strategic Development and Innovation, will present at the upcoming conference, ‘Clinical Trial Supply Forum’.

Catalent today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan.

Catalent announced a deal to acquire a clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan, from Teva-Takeda Pharmaceuticals, Nagoya Aichi, Japan.

Catalent today announced that it will present at the upcoming conference, ‘Outsourcing in Clinical Trials 2020 – A Virtual Experience’.

Catalent today welcomed the news by Humanigen, Inc., that it has dosed the first COVID-19 patient in its previously announced Phase 3 study for lenzilumab.